Tornado Infrastructure Equipment Ltd.
Share price: $1.92
17 years of history · ending 2025-10-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 2.40% | 1.40% | 2.00% | 1.80% | 2.20% | 1.60% |
| Foreign Rate Differential | -0.60% | -0.50% | -0.70% | -0.70% | -1.20% | -2.20% |
| Other Adjustments | -0.40% | -0.10% | -0.10% | 0.10% | -0.30% | -0.30% |
| R&D Tax Credits | 1.70% | 1.40% | 1.30% | 2.30% | 1.90% | 2.50% |
| FDII Deduction | — | 0.90% | 0.70% | 1.10% | 0.90% | 1.20% |
| Tax Law Change | 0.00% | 0.00% | — | — | — | — |
| Qualified Production Activities (Legacy DPAD) | 0.00% | 0.00% | — | — | — | — |
| Effective Tax Rate | 19.00% | 18.00% | 19.80% | 17.70% | 18.30% | 16.30% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $77.4M | $89.9M | $109.2M | $70.8M | $93.9M | $61.5M |
| Income Taxes Paid (Cash) | $69.5M | $101.8M | $120.5M | $165.2M | $91.7M | $106.4M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Share price: $1.92
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2025-10-31
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| End User Financing | $4M | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).